{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:57:39Z","timestamp":1787500659756,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009129","name":"Evidence Synthesis Programme","doi-asserted-by":"publisher","award":["NIHR135653"],"award-info":[{"award-number":["NIHR135653"]}],"id":[{"id":"10.13039\/501100009129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s41669-023-00439-6","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T14:02:28Z","timestamp":1695218548000},"page":"863-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-8704","authenticated-orcid":false,"given":"Marty","family":"Chaplin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-1535","authenticated-orcid":false,"given":"Rebecca","family":"Bresnahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-9779","authenticated-orcid":false,"given":"Nigel","family":"Fleeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-1003","authenticated-orcid":false,"given":"James","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-7732","authenticated-orcid":false,"given":"Rachel","family":"Houten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-103X","authenticated-orcid":false,"given":"Sophie","family":"Beale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-8644","authenticated-orcid":false,"given":"Angela","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9847-1622","authenticated-orcid":false,"given":"Yenal","family":"Dundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9900-798X","authenticated-orcid":false,"given":"Pinki","family":"Munot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"439_CR1","unstructured":"National Institute for Health and Care Excellence. Highly specialised technologies guidance. 2023; Available at: https:\/\/www.nice.org.uk\/About\/What-we-do\/Our-Programmes\/NICE-guidance\/NICE-highly-specialised-technologies-guidance. Accessed 12 July 2023."},{"key":"439_CR2","unstructured":"National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating spinal muscular atrophy: Highly specialised technologies guidance [HST15]. 2021; Available at: https:\/\/www.nice.org.uk\/guidance\/hst15. Accessed 12 July 2023."},{"key":"439_CR3","unstructured":"National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy: highly specialised technologies guidance [HST24]. 2023. Available at: https:\/\/www.nice.org.uk\/guidance\/hst24. Accessed 12 July 2023."},{"issue":"4","key":"439_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346.","journal-title":"Neurol Clin"},{"issue":"6","key":"439_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391.","journal-title":"Ann Neurol"},{"issue":"3","key":"439_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Alias L, March F, Vencesla A, Rodriguez-Alvarez FJ, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"439_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315.","journal-title":"Neuromuscul Disord"},{"key":"439_CR8","unstructured":"National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy: Highly specialised technologies guidance [HST24]. Committee papers: company submission. 2023. Available at: https:\/\/www.nice.org.uk\/guidance\/hst24\/evidence\/committee-papers-pdf-11435069341. Accessed 12 July 2023."},{"key":"439_CR9","unstructured":"National Organization for Rare Disorders. Spinal muscular atrophy. 2023. Available at: https:\/\/rarediseases.org\/rare-diseases\/spinal-muscular-atrophy\/#subdivisions. Accessed 12 July 2023."},{"key":"439_CR10","unstructured":"European Medicines Agency. Zolgensma. Procedural steps taken and scientific information after the authorisation. 2020 [updated 14 November 2022]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/zolgensma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 12 July 2023."},{"key":"439_CR11","unstructured":"UK National Screening Committee. Antenatal and newborn screening programme. SMA. 2023; Available at: https:\/\/view-health-screening-recommendations.service.gov.uk\/sma\/. Accessed 12 July 2023."},{"key":"439_CR12","unstructured":"National Institute for Health and Care Excellence. Managed Access Agreement. Onasemnogene abeparvovec for pre-symptomatic 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene [HST15]. 2021; Available at: https:\/\/www.nice.org.uk\/guidance\/hst15\/resources\/managed-access-agreement-pdf-9191290285. Accessed 12 July 2023."},{"key":"439_CR13","unstructured":"University of Oxford Department of Paediatrics. First UK pilot study of newborn screening for spinal muscular atrophy (SMA) launched in Oxford. 2022. Available at: https:\/\/www.paediatrics.ox.ac.uk\/news\/first-uk-pilot-study-of-newborn-screening-for-spinal-muscular-atrophy-sma-launched-in-oxford. Accessed 12 July 2023."},{"key":"439_CR14","unstructured":"Novartis. Data on file. UK Clinical Advisory Board: summary report. 17 March 2022."},{"key":"439_CR15","unstructured":"National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (MAA partial review of HST 15) [ID4051]. Final scope. 2022; Available at: https:\/\/www.nice.org.uk\/guidance\/gid-hst10053\/documents\/final-scope. Accessed 12 July 2023."},{"issue":"3","key":"439_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197\u2013207.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"439_CR17","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. The phase III SPR1NT trial: onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1. Nat Med. 2022;28(7):1381\u20139.","journal-title":"Nat Med"},{"issue":"7","key":"439_CR18","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. The phase III SPR1NT trial: onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy. Nat Med. 2022;28(7):1390\u20137.","journal-title":"Nat Med"},{"key":"439_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02379.x","volume":"450","author":"World Health Organization Multicentre Growth Reference Study Group","year":"2006","unstructured":"World Health Organization Multicentre Growth Reference Study Group. WHO motor development study: windows of achievement for six gross motor development milestones. Acta Paediatr. 2006;450:86\u201395.","journal-title":"Acta Paediatr"},{"key":"439_CR20","unstructured":"Novartis. Data on file. PNCR and NeuroNext database report. Novartis; 2018."},{"issue":"2","key":"439_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019;54(2):179\u201385.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"439_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"issue":"10","key":"439_CR23","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832\u201341.","journal-title":"Lancet Neurol"},{"key":"439_CR24","unstructured":"National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy: Highly specialised technologies guidance [HST24]. Committee papers: EAG report. 2023. Available at: https:\/\/www.nice.org.uk\/guidance\/hst24\/evidence\/committee-papers-pdf-11435069341. Accessed 12 July 2023."},{"key":"439_CR25","unstructured":"National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating spinal muscular atrophy. Highly specialised technologies guidance. Available at: https:\/\/www.nice.org.uk\/guidance\/hst15\/resources\/onasemnogene-abeparvovec-for-treating-spinal-muscular-atrophy-pdf-50216260528069. Accessed 30 Aug 2022."},{"key":"439_CR26","unstructured":"Novartis. Annex I. Summary of product characteristics. Zolgensma. 2020 [updated 14 November 2022]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zolgensma-epar-product-information_en.pdf. Accessed 12 July 2023."},{"key":"439_CR27","unstructured":"ClinicalTrials.gov. Single-dose gene replacement therapy using for patients with spinal muscular atrophy type 1 with one or two SMN2 copies [NCT03837184]. 2019 [updated 22 November 2022]. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03837184. Accessed 12 July 2023."},{"key":"439_CR28","unstructured":"Terry M. Novartis reveals two deaths related to SMA drug Zolgensma. 2022; Available at: https:\/\/www.biospace.com\/article\/novartis-reveals-two-more-deaths-related-to-sma-drug-zolgensma\/. Accessed 12 July 2023."},{"issue":"15","key":"439_CR29","doi-asserted-by":"publisher","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","volume":"94","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, van Eijk RPA, Cuppen I, Veldhoen ES, et al. Population-based analysis of survival in spinal muscular atrophy. Neurology. 2020;94(15):e1634\u201344.","journal-title":"Neurology"},{"issue":"3","key":"439_CR30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M, Bartels B, Otto LAM, Lemmink HH, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur J Neurol. 2018;25(3):512\u20138.","journal-title":"Eur J Neurol"},{"key":"439_CR31","unstructured":"ClinicalTrials.gov. Long-term follow-up study of patients receiving onasemnogene abeparvovec-xioi [NCT04042025]. 2019 [updated 5 December 2022]. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04042025. Accessed 12 July 2023."},{"key":"439_CR32","unstructured":"Office for National Statistics. National life tables - life expectancy in the UK: 2018 to 2020. Available at: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2018to2020. Accessed 12 July 2023."},{"issue":"5","key":"439_CR33","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Chiarini Testa MB, Mastella C, Rava L, Bignamini E, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131(5):e1509\u201314.","journal-title":"Pediatrics"},{"key":"439_CR34","unstructured":"Edwards SJ, Kew K, Karner M, Jhita C, Arceniuk G. Onasemnogene abeparvovec for treating spinal muscular atrophy type 1: a highly specialised technology appraisal. Available at: https:\/\/www.nice.org.uk\/guidance\/hst15\/documents\/committee-papers.  Accessed 15 September 2023."},{"key":"439_CR35","doi-asserted-by":"crossref","unstructured":"Thompson R, Vaidya S, Teynor M. The utility of different approachs to developing health utilities data in childhood rare diseases; a case study in spinal muscular atrophy (SMA). Presented at the ISPOR 20th Annual European Congress, 4\u20138 November 2017; Glasgow.","DOI":"10.1016\/j.jval.2017.08.1962"},{"key":"439_CR36","unstructured":"Tappenden P, Hamilton J, Kaltenthaler E, Hock E, Rawdin A, Mukuria C, et al. Nusinersen for treating spinal muscular atrophy: a single technology appraisal. Available at: https:\/\/www.nice.org.uk\/guidance\/ta588\/documents\/committee-papers. Accessed 12 July 2023."},{"issue":"5","key":"439_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318.","journal-title":"Value Health."},{"key":"439_CR38","unstructured":"Department of Health Social Care. National Schedule of NHS Costs 2019\/20. Updated 2020. Available at: https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fwww.england.nhs.uk%2Fwp-content%2Fuploads%2F2021%2F06%2FNational_Schedule_of_NHS_Costs_FY1920.xlsx&wdOrigin=BROWSELINK. Accessed 12 July 2023."},{"key":"439_CR39","unstructured":"National Health Service Business Services Authority. Prescription cost analysis - England - 2021\/22. 2022. Available at: https:\/\/www.nhsbsa.nhs.uk\/statistical-collections\/prescription-cost-analysis-england\/prescription-cost-analysis-england-202122. Accessed 12 July 2023."},{"key":"439_CR40","unstructured":"Personal Social Services Research Unit. Unit Costs of Health and Social Care 2021. Available at: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-of-health-and-social-care-2021\/. Accessed 12 July 2023."},{"issue":"6","key":"439_CR41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1365-2524.2006.00639.x","volume":"14","author":"J Noyes","year":"2006","unstructured":"Noyes J, Godfrey C, Beecham J. Resource use and service costs for ventilator-dependent children and young people in the UK. Health Soc Care Community. 2006;14(6):508\u201322.","journal-title":"Health Soc Care Community"},{"key":"439_CR42","unstructured":"Novartis. Community statement from Novartis Gene Therapies UK: NHS is temporarily pausing Zolgensma treatment in NHS-covered children older than 12 months. 2022. Available at: https:\/\/smauk.org.uk\/files\/files\/Research\/Community%20Statement%20from%20Novartis%20UK%20Dec%202022.pdf. Accessed 12 July 2023."},{"key":"439_CR43","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2022. Available at: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation. Accessed 12 July 2023."},{"key":"439_CR44","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2022. Available at: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation. Accessed 30 Mar 2023."}],"updated-by":[{"DOI":"10.1007\/s41669-023-00462-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000}}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-023-00439-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T02:03:35Z","timestamp":1702605815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-023-00439-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1007\/s41669-023-00439-6","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"3 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s41669-023-00462-7","URL":"https:\/\/doi.org\/10.1007\/s41669-023-00462-7","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was funded by the National Institute for Health Research Evidence Synthesis Programme as project number NIHR135653 (see the Evidence Synthesis Programme website for further project information \u2013\n                      \n                      . The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the NICE or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden and Pinki Munot have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"MC: Critical appraisal of the clinical and statistical evidence, drafted versions of the paper. RB: Project lead, critical appraisal of the clinical evidence and supervised the final report. NF: Critical appraisal of the clinical evidence. JM: Critical appraisal of the economic model. RH: Critical appraisal of the economic model. SB: Critical appraisal of the clinical and economic evidence, editorial input. AB: Critical appraisal of the clinical and economic evidence, editorial input. YD: Critical appraisal of the company\u2019s search strategies. AM: Critical appraisal of the company submission, PM: Clinical advice and critical appraisal of the clinical evidence.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}